Clinical trial
Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis
NCT05524311 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 10, 2022
- Completion date
- January 2, 2026
- Enrollment
- 16 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.
juvenile dermatomyositis